We report the discovery of a novel series of 3-cinnoline carboxamides as highly potent and selective ATM inhibitors. Optimisation of this series focusing on potency and physicochemical properties (especially permeability) led to the identification of compound 21, a highly potent ATM inhibitor (ATM cell IC50 0.0028 μM) with excellent kinase selectivity and favourable physicochemical and pharmacokinetics properties. In vivo, 21 in combination with irinotecan showed tumour regression in the SW620 colorectal tumour xenograft model, superior inhibition to irinotecan alone. Compound 21 was selected for pre-clinical evaluation alongside AZD0156.